Epstein-Barr Virus Latent Membrane Protein 1 Suppresses Ferroptosis via Pentose Phosphate Pathway and Glutathione Metabolism

This study reveals that the Epstein-Barr virus oncogene LMP1 confers resistance to ferroptosis in infected B cells by activating the TES2 signaling domain to upregulate PFKFB4, thereby enhancing pentose phosphate pathway flux and glutathione metabolism to bolster redox defense.

The Gist

The Big Picture: A Viral Hijacker and a Cell's "Fire Extinguisher"

Imagine your body's immune system is a city, and the Epstein-Barr Virus (EBV) is a notorious criminal gang that breaks into the city's police stations (your B-cells). Once inside, the gang doesn't just hide; they take over the station, force the officers to work overtime, and turn them into a super-charged, unstoppable factory that produces more gang members. This is how EBV causes certain cancers, like lymphoma.

But there's a problem for the gang: their new "factory" is running so hot and fast that it's generating a lot of dangerous exhaust fumes called Lipid ROS (Reactive Oxygen Species). If these fumes aren't cleaned up, they will burn the factory down from the inside, killing the gang members. This self-destruction process is called Ferroptosis.

This paper discovers exactly how the virus builds a super-strong fire extinguisher to keep its factories from burning down.

---

The Key Players

1. The Virus (EBV): The criminal gang leader.
2. LMP1: The virus's "Boss" protein. It's like the foreman on the factory floor who tells the workers what to do.
3. Ferroptosis: The "Self-Destruct Button." It's a specific way cells die when they get too much oxidative stress (like a fire).
4. Erastin: A drug that acts like a "gas valve." It tries to cut off the supply of a specific fuel (cysteine) the cell needs to make its fire extinguisher.
5. PFKFB4: The star of this story. It's a host enzyme (a machine inside the cell) that the virus hijacks to build a better fire extinguisher.

---

The Story Unfolds

1. The Virus Builds a Shield

The researchers found that when EBV infects a B-cell, the cell becomes very sensitive to the "gas valve" drug (erastin). It's like a car with a tiny fuel tank; if you block the fuel line, the car stops immediately.

However, once the virus fully takes over and starts expressing its LMP1 protein, the cell becomes tough. It can survive even when the fuel line is blocked. The virus has learned how to keep the engine running without the usual fuel.

2. The Secret Weapon: The "TES2" Switch

The LMP1 protein has two main control switches, called TES1 and TES2.

• The researchers tested these switches and found that TES2 is the magic key.
• Even though LMP1 looks a lot like a natural signal the body uses (called CD40), it does something unique. The body's natural signal doesn't protect the cell from the fire, but the virus's LMP1 does.
• Specifically, the TES2 part of LMP1 is what tells the cell to build its defense system.

3. The Fuel Crisis and the Solution

To stop the fire (ferroptosis), the cell needs a chemical called Glutathione. Think of Glutathione as the water in the fire extinguisher.

• To make Glutathione, the cell needs Cysteine (the raw material).
• To turn Cysteine into Glutathione, the cell needs NADPH (the energy battery).

The virus, via the TES2 switch, realizes the cell is running low on batteries (NADPH). So, it pulls a lever to activate a specific machine inside the cell called PFKFB4.

4. PFKFB4: The Traffic Cop

Imagine the cell's energy production as a busy highway with two exits:

• Exit A (Glycolysis): A fast road that produces energy quickly but doesn't help with the fire extinguisher.
• Exit B (Pentose Phosphate Pathway): A slower road that produces the NADPH batteries needed to make the fire extinguisher.

Normally, most traffic goes down Exit A. But when the virus activates PFKFB4, it acts like a traffic cop that blocks Exit A and forces all the cars to take Exit B.

• This floods the cell with NADPH batteries.
• With plenty of batteries, the cell can convert whatever Cysteine it has into Glutathione.
• Now, even if the drug (erastin) tries to cut off the Cysteine supply, the cell has so many batteries and so much stored Glutathione that it can keep fighting the fire.

5. The "Aha!" Moment

The researchers proved this by:

• Removing the Traffic Cop (PFKFB4): When they turned off PFKFB4 in virus-infected cells, the cells immediately lost their fire extinguisher. Even a tiny amount of the drug (erastin) killed them.
• Adding the Cop Back: When they forced the cells to make more PFKFB4, the cells became super-resistant again.

Why Does This Matter?

This discovery is a game-changer for treating cancers caused by EBV (like certain lymphomas).

• The Problem: These cancer cells are tough because they have this super-charged fire extinguisher (PFKFB4) built by the virus.
• The Solution: If doctors can find a way to block PFKFB4 (take away the traffic cop), they can force the cancer cells to go back to the slow road. The cancer cells will run out of batteries, their fire extinguisher will fail, and they will burn themselves up (die by ferroptosis).

The Takeaway Analogy

Think of the virus as a arsonist who sets a fire in a building. To survive, the arsonist installs a high-tech sprinkler system (LMP1/TES2) that uses a special pump (PFKFB4) to draw water from a backup tank (NADPH).

This paper shows us exactly how that pump works. Now, instead of trying to put out the fire with a bucket (which doesn't work on these tough cells), we can simply cut the power to the pump. Without the pump, the sprinkler system fails, and the building (the cancer cell) burns down.

This gives scientists a new, very specific target to help destroy these stubborn cancers.

Technical Summary

1. Problem Statement

Epstein-Barr virus (EBV) is a major oncogenic driver associated with approximately 200,000 cancers annually, including Burkitt lymphoma and post-transplant lymphoproliferative disease (PTLD). While EBV is known to remodel host cell metabolism to support rapid B-cell proliferation, the mechanisms by which it protects infected cells from ferroptosis—a form of programmed cell death driven by lipid reactive oxygen species (ROS)—remain poorly understood.

Previous studies established that newly infected B-cells undergoing "Burkitt-like" hyperproliferation are exquisitely sensitive to ferroptosis, particularly when cystine uptake is blocked. However, as cells transform into immortalized lymphoblastoid cell lines (LCLs) and express the viral oncoprotein Latent Membrane Protein 1 (LMP1), they become resistant to ferroptosis. The specific signaling pathways and metabolic targets through which LMP1 confers this resistance were unknown.

2. Methodology

The authors employed a multi-disciplinary approach combining virology, cell biology, metabolomics, and CRISPR-Cas9 genetics:

• Cell Models: Used Daudi and Akata Burkitt lymphoma cells (with inducible LMP1/LMP2A expression), Mutu I (Latency I) vs. Mutu III (Latency III) cells, and primary human B-cells infected with wild-type (WT) or mutant EBV strains.
• Genetic Engineering:
  • Generated EBV BAC (Bacterial Artificial Chromosome) mutants with specific point mutations in LMP1 to abrogate TES1 (Transformation Effector Site 1) or TES2 signaling.
  • Utilized CRISPR-Cas9 to knock down host genes (e.g., PFKFB4, TRAF6, TAK1) and LMP1 in LCLs.
  • Created doxycycline-inducible systems for LMP1, LMP2A, and PFKFB4 overexpression.
• Ferroptosis Induction & Assays:
  • Treated cells with Erastin (inhibits cystine uptake via SLC7A11) and ML-210 (inhibits GPX4).
  • Measured cell viability via 7-AAD uptake (flow cytometry) and CellTiter-Glo.
  • Quantified lipid ROS using BODIPY 581/591 C-11 staining.
• Metabolomics & Transcriptomics:
  • Performed LC-MS/MS to profile metabolites (cystine, glutathione, NADPH, PPP intermediates).
  • Conducted RNA-seq to identify differentially expressed genes in WT vs. TES2-mutant infected cells.
• Biochemical Assays: Measured glutathione (GSH) levels, NADPH/NADP+ ratios, and cystine uptake rates.

3. Key Contributions

The study identifies a novel, non-canonical metabolic axis driven by the EBV oncoprotein LMP1 that is critical for tumor cell survival:

1. LMP1-Specific Ferroptosis Resistance: Demonstrated that LMP1, but not LMP2A or canonical CD40 signaling, is sufficient to confer resistance to erastin-induced ferroptosis.
2. TES2 Signaling Dependency: Mapped the resistance phenotype specifically to the TES2/CTAR2 region of the LMP1 C-terminal tail, independent of canonical NF-κB signaling.
3. Identification of PFKFB4: Identified PFKFB4 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4) as the critical host metabolic target upregulated by TES2 signaling.
4. Metabolic Mechanism Elucidation: Defined the mechanism as a shift in glucose metabolism toward the Pentose Phosphate Pathway (PPP) to boost NADPH, which is essential for maintaining reduced glutathione (GSH) pools and detoxifying lipid ROS.

4. Detailed Results

A. LMP1 Confers Resistance to Erastin via TES2

• Induction of LMP1 in Burkitt cells (Daudi, Akata) rendered them resistant to erastin (SLC7A11 inhibitor) but not to ML-210 (GPX4 inhibitor).
• This resistance was dependent on the TES2 signaling domain. Cells expressing LMP1 mutants lacking TES2 function (TES2m) remained sensitive to erastin, whereas TES1 mutants retained resistance.
• Canonical NF-κB inhibition (using IKKβ inhibitors) did not reverse LMP1-mediated resistance, suggesting a distinct, non-canonical pathway.

B. Metabolic Remodeling: Glutathione and NADPH

• Metabolomics: LMP1 expression (and Latency III program) significantly increased intracellular reduced glutathione (GSH) and depleted cystine (indicating high uptake/consumption).
• TES2 Requirement: In primary B-cells infected with TES2m EBV, GSH levels were significantly lower, and cystine uptake was impaired compared to WT EBV infection.
• NADPH Depletion: TES2 signaling was required to maintain high NADPH/NADP+ ratios. Loss of TES2 led to reduced NADPH, which is the electron donor required to reduce cystine to cysteine and to regenerate GSH from GSSG.

C. PFKFB4 is the Key Effector

• Transcriptomics: RNA-seq of TES2m vs. WT infected cells revealed PFKFB4 as one of the most significantly downregulated genes in the absence of TES2 signaling.
• Mechanism: PFKFB4 acts as a phosphatase that converts Fructose-2,6-bisphosphate (F2,6BP) back to Fructose-6-phosphate. This shunts glycolytic flux away from glycolysis and into the Pentose Phosphate Pathway (PPP), the primary source of cellular NADPH.
• Validation:
  • Knockdown of PFKFB4 in LCLs increased lipid ROS, decreased GSH, and sensitized cells to erastin.
  • Overexpression of PFKFB4 in TES2m-infected cells rescued their growth defects and restored resistance to erastin.
  • LMP1 expression directly upregulates PFKFB4 protein and mRNA levels.

D. Therapeutic Implications

• The study suggests that EBV-driven lymphomas (which express LMP1) are dependent on PFKFB4 for redox homeostasis.
• Inhibiting PFKFB4 could resensitize these tumors to ferroptosis, offering a potential therapeutic strategy for EBV-associated malignancies.

5. Significance

• Novel Viral Mechanism: This work reveals that EBV has evolved a specific mechanism (via LMP1-TES2) to hijack host metabolism (PFKFB4/PPP) specifically to counteract the oxidative stress generated by its own oncogenic drive. This distinguishes viral redox defense from standard cellular responses.
• Metabolic Vulnerability: It identifies PFKFB4 as a critical "Achilles' heel" in EBV-positive lymphomas. Since these tumors rely on PFKFB4 to survive ferroptosis, targeting this enzyme could be a selective therapeutic strategy.
• Ferroptosis in Cancer: The findings expand the understanding of how cancer cells evade ferroptosis, highlighting the interplay between viral oncogenes, the pentose phosphate pathway, and glutathione metabolism.
• Clinical Relevance: The study proposes a combination therapy approach: inhibiting PFKFB4 to deplete NADPH/GSH reserves, thereby sensitizing EBV+ lymphomas (e.g., PTLD, Burkitt lymphoma, Hodgkin lymphoma) to ferroptosis-inducing agents like erastin.

In summary, the paper establishes that LMP1-TES2 signaling drives PFKFB4 expression, which shunts glucose to the PPP to generate NADPH, thereby sustaining glutathione pools and protecting EBV-infected B-cells from ferroptosis.